<DOC>
	<DOCNO>NCT00302536</DOCNO>
	<brief_summary>The purpose study assess efficacy Tacrolimus Treatment patient idiopathic focal segmental glomerulosclerosis .</brief_summary>
	<brief_title>Tacrolimus Treatment Patients With Idiopathic Focal Segmental Glomerulosclerosis</brief_title>
	<detailed_description>Primary FSGS lead cause end stage renal disease adult , complete loss kidney function 50 % patient 10 year . Steroids , currently use treat disease , effective part patient . Over past decade , number study report therapeutic efficacy treatment Cyclosporine-A ( CSA ) patient FSGS . Recent study suggest immunosuppressive therapy target calcineurin pathway T-helper cell , example , tacrolimus , may effective treatment primary FSGS . The experience Tacrolimus ( FK506 ) treatment patient FSGS limit uncontrolled trial adult patient .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Age 1450 year onset sign symptom FSGS Biopsy proven FSGS Estimated glomerular filtration rate ( GFR ) â‰¥ 40 ml/min/1.73 m2 Urine protein &gt; 3.5 g/24h Biopsy confirm primary FSGS ( include subtypes ) Willingness follow clinical trial protocol , include medication , baseline followup visit procedure Secondary FSGS Prior therapy sirolimus , CSA , MMF , azathioprin , cytoxan , chlorambucil levamisole , methotrexate , nitrogen mustard last 90 day Active/serious infection Malignancy Previously diagnose diabetes mellitus type 1 2 Clinical evidence cirrhosis chronic active liver disease History significant gastrointestinal disorder Allergy study medication , Inability consent/assent</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Idiopathic Focal Segmental Glomerulosclerosis</keyword>
	<keyword>Treatment</keyword>
	<keyword>Steroids</keyword>
</DOC>